September 10, 2024

JCA update: FIECON experts keeping you in the loop about JCA.

Stay informed with our analysis of the latest JCA updates and their impact on healthcare policy.
Key update: June 2024

A reminder of the scope and key dates

In our post "What is Joint Clinical Assessment (JCA) process and how will it impact your product launch?", we shared that starting on 12th January 2025, medicinal products under Article 7(2), point (a) of Regulation (EU) 2021/2282 will undergo Joint Clinical Assessment (JCA). Initially, this includes new active substances for cancer treatment and advanced therapy medicinal products. By 13th January 2028, all orphan medicinal products and by 13th January 2030, all other medicinal products under Article 7 will be included.

PICOs deadline

The scope of the JCA assessment is defined through PICOs (Population, Intervention, Comparator, Outcomes) development, which consolidates diverse needs from all member states into several PICOs. Once these PICOs are communicated to pharmaceutical companies, they have only 100 days to submit the JCA dossier. This deadline is especially challenging given the need to conduct systematic literature reviews (SLRs) on all of the PICOs.

Guidance and identification

The EMA’s guidance, published on 21st June 2024, instructs manufacturers who have a product indicated for the treatment of cancer or which are designated to be an ATMP on declaring their application’s scope concerning the HTA Regulation via the EMA Letter of Intent. The Member State Co-ordination Group on Health Technology Assessment also provided a document to help identify products subject to JCA from 2025.

Notification process

Applicants must notify the HTACG secretariat at SANTE-HTA-JCA@ec.europa.eu, requesting access to the HTA IT Platform for uploading the EMA Letter of Intent. The email should include the health technology developer’s contact details linked to their EU Login account. Upon receipt, HTACG will provide an upload link and acknowledge the submission. Each product requires a separate upload link.

Still in the dark about JCA? Everything you always wanted to know about JCA is here. Check out our JCA fundaments page to learn more.

Will your next EU product launch face tight deadlines with the JCA? Check out Our JCA solution page to get started.

Company updates

Learning insights: Blended Survival Analysis
Why do we need blended survival analysis and what are the benefits and challenges?
Read more
Key insights: Future Cancer Inquiry
Future Cancer: NICE Medicines Appraisal (Enhertu), HC 739 was discussed with the committee and representatives from Pharma about the changes by NICE in 2022 to assess the cost-effectiveness of drugs.
Read more
Key Insights: Advanced Therapies 2024
The Advanced Therapies Congress is Europe’s largest commercial cell and gene therapy conference and exhibition. The event is for the leaders of pioneering ATMP companies and their most senior executives in charge of the latest tech and strategies.
Read more